The crucial data readouts coming soon for small biotechs
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Akero’s success gives a new Nash mechanism hope
Before Covid-19 came along investors were looking to several Nash catalysts in 2020, and yesterday Akero delivered on one of these.
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Upcoming events – Gilead’s Nash refocus and an early chance for Ionis and Roche
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
Cymabay is out, but for Genfit the band plays on
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Genfit’s liver disease Hail Mary approaches
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
